- Home
- NRGV vs KURA Comparison
NRGV vs KURA Comparison
Compare NRGV & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$5.79
HOLD
Current Price
$8.50
Company Overview
Basic Information| Metric | NRGV | KURA |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 887.6M | 830.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NRGV | KURA |
|---|---|---|
| Price | $5.79 | $8.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $1.75 | ★ $26.88 |
| AVG Volume (30 Days) | ★ 3.4M | 1.6M |
| Earning Date | 11-10-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $83,836,000.00 | ★ $104,029,000.00 |
| Revenue This Year | $322.22 | $109.64 |
| Revenue Next Year | $29.01 | $62.82 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.60 | $5.41 |
| 52 Week High | $6.35 | $12.49 |
Technical Indicators
Market Signals| Indicator | NRGV | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 62.36 | 32.26 |
| Support Level | $5.00 | $8.92 |
| Resistance Level | $6.35 | $9.43 |
| Average True Range (ATR) | 0.49 | 0.48 |
| MACD | 0.04 | -0.13 |
| Stochastic Oscillator | 70.62 | 1.59 |
Price Performance
Historical Comparison NRGV
KURA
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.